The development of blood vessels by the process of angiogenesis underpins the growth and
metastasis of many tumour types. Various angiogenesis inhibitors targeted against vascular …

Since its inception more than three decades ago, the field of angiogenesis research has
made significant progress (1). During tumorigenesis, the process of angiogenesis, which is …

Despite great efforts and resources being devoted to treatment, the incidence and mortality
of numerous cancers have not decreased in recent decades. This is a result of the …

Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …

Angiogenesis inhibition by monoclonal antibodies against vascular endothelial growth factor
receptor (VEGFR) combined with cytotoxic chemotherapy has shown encouraging potential …

Clinical trials using antiangiogenic drugs revealed their potential against cancer.
Unfortunately, a large percentage of patients does not yet benefit from this therapeutic …

Formation of new blood vessels, ie angiogenesis, is essential for the development and
growth of solid tumors (Folkman 1971, 1986, 1995). Tumor angiogenesis results from an …

Angiogenesis inhibitors combined with cytotoxic chemotherapy have recently entered
routine oncological practice. Several rationales exist for combining these agents with …

A continuously expanding vasculature is an essential requirement of a growing neoplastic
mass. The blood-vessel network provides not only nutritional support and waste product …

The importance of tumoral vascularization as a therapeutic target was first described in 1971
by Folkman. Anarchic vascularization in response to tumour hypoxia, especially mediated by …